ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Potassium Carbonate → (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione

HRID 736944
ノート
印刷プレビュー

反応式

HRID 736944 の反応式
[CH3:1][N:2]1[CH:7]2[CH2:8][CH2:9][CH:3]1[CH2:4][CH:5]([N:10]1[CH2:15][CH2:14][NH:13][CH2:12][CH2:11]1)[CH2:6]2.[NH2:16][C:17]1[C:48]([C:49]([F:52])([F:51])[F:50])=[CH:47][C:20]([CH2:21][C@@H:22]([CH2:26][C:27](=[O:46])[N:28]2[CH2:33][CH2:32][CH:31]([N:34]3[CH2:40][CH2:39][C:38]4[CH:41]=[CH:42][CH:43]=[CH:44][C:37]=4[NH:36][C:35]3=[O:45])[CH2:30][CH2:29]2)[C:23](O)=[O:24])=[CH:19][C:18]=1[Cl:53].CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.C(N(C(C)C)C(C)C)C.C([O-])([O-])=O.[K+].[K+]>CN(C=O)C>[NH2:16][C:17]1[C:48]([C:49]([F:51])([F:50])[F:52])=[CH:47][C:20]([CH2:21][C@@H:22]([CH2:26][C:27]([N:28]2[CH2:33][CH2:32][CH:31]([N:34]3[CH2:40][CH2:39][C:38]4[CH:41]=[CH:42][CH:43]=[CH:44][C:37]=4[NH:36][C:35]3=[O:45])[CH2:30][CH2:29]2)=[O:46])[C:23]([N:13]2[CH2:14][CH2:15][N:10]([CH:5]3[CH2:6][CH:7]4[N:2]([CH3:1])[CH:3]([CH2:9][CH2:8]4)[CH2:4]3)[CH2:11][CH2:12]2)=[O:24])=[CH:19][C:18]=1[Cl:53]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 5

HCID 11430Potassium CarbonateHCID 81531DiisopropylethylamineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 154797638-Methyl-3-(piperazin-1-yl)-8-azabicyclo[3.2.1]octaneHCID 68591515(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butanoic acid

生成物 1

HCID 57848362(S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

850 mg (2.4 mmol) 8-methyl-3-piperazin-1-yl-8-aza-bicyclo[3.2.1]octan were added to a solution of 1.04 g (1.88 mmol) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butanoic acid, 642 mg (2.0 mmol) TBTU and 1.64 mL (9.6 mmol) ethyldiisopropylamine in 20 mL DMF and the reaction mixture was stirred overnight at RT. The reaction solution was combined with 15% K2CO3 solution, stirred for 10 min at RT, the precipitated substance was suction filtered, washed with 50 mL water and dried in the air and purified by chromatography (silica gel, gradient: DCM to DCM/MeOH/NH3 10:85:5).

後処理

  1. stirringstirred for 10 min at RT
  2. filtrationfiltered
  3. washwashed with 50 mL water
  4. customdried in the air
  5. custompurified by chromatography (silica gel, gradient: DCM to DCM/MeOH/NH3 10:85:5)

出典と根拠

ORDレコード
ord-c956c973a81b48c2b944cc644a99fbc9
出典データセット
uspto-grants-2009_09
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07595312B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート